Dicerna Pharmaceuticals reported $221.21M in Cash and Equivalent for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cash And Equivalent Change
Acceleron Pharma XLRN:US $ 336.2M 119.31M
Agenus AGEN:US $ 73.54M 45.82M
Alnylam Pharmaceuticals ALNY:US $ 745.77M 366.22M
Amgen AMGN:US $ 6630M 518M
Arrowhead Research ARWR:US $ 325.98M 46.4M
Biogen BIIB:US $ 1742M 524.5M
Bluebird Bio BLUE:US $ 353.47M 86.25M
Dicerna Pharmaceuticals DRNA:US $ 221.21M 62.1M
Exelixis EXEL:US $ 492.46M 122.25M
Gilead Sciences GILD:US $ 7361M 3296M
GlaxoSmithKline GSK:LN 3503M 1254M
Immunogen IMGN:US $ 239.54M 43.58M
Intercept Pharmaceuticals ICPT:US $ 145.62M 52.67M
Intrexon XON:US $ 36.41M 9.06M
IONIS PHARMACEUT IONS:US $ 565.12M 150.96M
Karyopharm Therapeutics KPTI:US $ 141.31M 52.84M
Lexicon Pharmaceuticals LXRX:US $ 118.5M 20.85M
Macrogenics MGNX:US $ 188.97M 29.53M
Mirati Therapeutics MRTX:US $ 258.99M 35.9M
Regeneron Pharmaceuticals REGN:US $ 2072.2M 634.3M
Regulus Therapeutics RGLS:US $ 41.44M 9.84M
Ultragenyx Pharmaceutical RARE:US $ 290.88M 92.92M